Domestic Radiopharmaceutical Company DuChemBio Achieves 20.9 Billion Won in First-Half Revenue
DuChemBio, the leading company in the domestic radiopharmaceutical sector, has announced its financial results for the first half of this year. According to data released on the 18th, DuChemBio recorded 20.9 billion won in revenue and 3.2 billion won in operating profit for the first half of the year.
DuChemBio is a company that specializes in producing radiopharmaceuticals necessary for diagnosing diseases such as cancer and dementia. These results demonstrate that the company is consistently growing in the domestic market.
Radiopharmaceuticals are essential medical resources for accurately checking a patient's internal physical condition. By providing a stable supply of these pharmaceuticals, DuChemBio is contributing to the improvement of the domestic medical environment.
Moving forward, DuChemBio plans to help more patients through technological development and production expansion. Based on this first-half performance, industry attention is focused on whether the company can continue its stable growth in the second half of the year.